180 related articles for article (PubMed ID: 28750665)
1. Renal damage induced by pemetrexed causing drug discontinuation: a case report and review of the literature.
Sbitti Y; Chahdi H; Slimani K; Debbagh A; Mokhlis A; Albouzidi A; Bennani F; Errihani H; Ichou M
J Med Case Rep; 2017 Jul; 11(1):182. PubMed ID: 28750665
[TBL] [Abstract][Full Text] [Related]
2. Pemetrexed-induced acute kidney injury leading to chronic kidney disease.
Chauvet S; Courbebaisse M; Ronco P; Plaisier E
Clin Nephrol; 2014 Dec; 82(6):402-6. PubMed ID: 24424085
[TBL] [Abstract][Full Text] [Related]
3. Unusually prolonged pemetrexed cytotoxicity in a patient with a lung adenocarcinoma: a case report.
Sakhri L; Pinsolle J; Moro-Sibilot D; Pluchart H
J Med Case Rep; 2017 Sep; 11(1):262. PubMed ID: 28915906
[TBL] [Abstract][Full Text] [Related]
4. Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven.
Izzedine H; Escudier B; Rouvier P; Gueutin V; Varga A; Bahleda R; Soria JC
Ann Oncol; 2013 Sep; 24(9):2421-5. PubMed ID: 23798615
[TBL] [Abstract][Full Text] [Related]
5. Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer.
Shen L; Niu X; Jian H; Xu Y; Yu Y; Lu S
Lung Cancer; 2017 Sep; 111():43-50. PubMed ID: 28838396
[TBL] [Abstract][Full Text] [Related]
6. Interstitial nephritis and nephrogenic diabetes insipidus in a patient treated with pemetrexed.
Stavroulopoulos A; Nakopoulou L; Xydakis AM; Aresti V; Nikolakopoulou A; Klouvas G
Ren Fail; 2010; 32(8):1000-4. PubMed ID: 20722569
[TBL] [Abstract][Full Text] [Related]
7. Alectinib (Alecensa)-induced reversible grade IV nephrotoxicity: a case report and review of the literature.
Ramachandran P; Morcus R; Tahir M; Onukogu I; Spinowitz B; Wang JC
J Med Case Rep; 2018 Oct; 12(1):303. PubMed ID: 30336782
[TBL] [Abstract][Full Text] [Related]
8. Pemetrexed-induced acute renal failure, nephrogenic diabetes insipidus, and renal tubular acidosis in a patient with non-small cell lung cancer.
Vootukuru V; Liew YP; Nally JV
Med Oncol; 2006; 23(3):419-22. PubMed ID: 17018900
[TBL] [Abstract][Full Text] [Related]
9. Renal failure during chemotherapy: renal biopsy for assessing subacute nephrotoxicity of pemetrexed.
Assayag M; Rouvier P; Gauthier M; Costel G; Cluzel P; Mercadal L; Deray G; Isnard Bagnis C
BMC Cancer; 2017 Nov; 17(1):770. PubMed ID: 29145816
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of home delivery of pemetrexed in patients with advanced non-squamous non-small cell lung cancer.
Lal R; Hillerdal GN; Shah RN; Crosse B; Thompson J; Nicolson M; Vikström A; Potter VA; Visseren-Grul C; Lorenzo M; D'yachkova Y; Bourayou N; Summers YJ
Lung Cancer; 2015 Aug; 89(2):154-60. PubMed ID: 26101013
[TBL] [Abstract][Full Text] [Related]
11. Estimated Creatinine Clearance Rate Is Associated With the Treatment Effectiveness and Toxicity of Pemetrexed As Continuation Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Chen CY; Lin JW; Huang JW; Chen KY; Shih JY; Yu CJ; Yang PC
Clin Lung Cancer; 2015 Nov; 16(6):e131-40. PubMed ID: 25659505
[TBL] [Abstract][Full Text] [Related]
12. Pemetrexed induced acute kidney injury in patients with non-small cell lung cancer: reversible and chronic renal damage.
Rombolà G; Vaira F; Trezzi M; Chiappini N; Falqui V; Londrino F
J Nephrol; 2015 Apr; 28(2):187-91. PubMed ID: 24986522
[TBL] [Abstract][Full Text] [Related]
13. Pemetrexed-induced Interstitial Lung Disease Mimicking Hypersensitivity Pneumonia: A Pathologically Proven Case.
Otoshi R; Sekine A; Hagiwara E; Okudela K; Katano T; Aiko N; Matama G; Isomoto K; Ikeda S; Baba T; Komatsu S; Ogura T
Intern Med; 2019 Sep; 58(18):2679-2682. PubMed ID: 31178492
[TBL] [Abstract][Full Text] [Related]
14. Posterior reversible encephalopathy syndrome possibly induced by pemetrexed maintenance therapy for lung cancer: a case report and literature review.
Smets GJ; Loyson T; Van Paesschen W; Demaerel P; Nackaerts K
Acta Clin Belg; 2018 Oct; 73(5):382-388. PubMed ID: 29173113
[TBL] [Abstract][Full Text] [Related]
15. Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study.
Nishimoto K; Karayama M; Inui N; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inami N; Matsuura S; Kaida Y; Matsui T; Asada K; Matsuda H; Fujii M; Toyoshima M; Imokawa S; Suda T
Med Oncol; 2018 Jun; 35(7):108. PubMed ID: 29909581
[TBL] [Abstract][Full Text] [Related]
16. Aplastic anemia in a lung adenocarcinoma patient receiving pemetrexed.
Matama G; Tokito T; Takeoka H; Hiraoka Y; Matsuo N; Nakamura M; Ishii H; Kinoshita T; Azuma K; Yamada K; Hoshino T
Invest New Drugs; 2017 Oct; 35(5):662-664. PubMed ID: 28361276
[TBL] [Abstract][Full Text] [Related]
17. Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
Pujol JL; Paz-Ares L; de Marinis F; Dediu M; Thomas M; Bidoli P; Corral J; San Antonio B; Chouaki N; John W; Zimmermann A; Visseren-Grul C; Gridelli C
Clin Lung Cancer; 2014 Nov; 15(6):418-25. PubMed ID: 25104617
[TBL] [Abstract][Full Text] [Related]
18. Renal Immune-related Adverse Event of Pembrolizumab Masked by Pemetrexed.
Nagase K; Murai Y; Yokoyama-Kokuryo W; Nagasaka T; Sato Y; Watanabe T; Ito Y; Nagase F; Fujita Y
Intern Med; 2024 Jan; 63(2):265-270. PubMed ID: 37258166
[TBL] [Abstract][Full Text] [Related]
19. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
Greenhalgh J; McLeod C; Bagust A; Boland A; Fleeman N; Dundar Y; Oyee J; Dickson R; Davis H; Green J; McKenna E; Pearson M
Health Technol Assess; 2010 Oct; 14(Suppl. 2):33-9. PubMed ID: 21047489
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer.
Tamiya M; Tamiya A; Kaneda H; Nakagawa K; Yoh K; Goto K; Okamoto H; Shimokawa T; Abe T; Tanaka H; Daga H; Takeda K; Hirashima T; Atagi S
Med Oncol; 2016 Jan; 33(1):2. PubMed ID: 26603297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
